JP2013067635A5 - - Google Patents

Download PDF

Info

Publication number
JP2013067635A5
JP2013067635A5 JP2012255810A JP2012255810A JP2013067635A5 JP 2013067635 A5 JP2013067635 A5 JP 2013067635A5 JP 2012255810 A JP2012255810 A JP 2012255810A JP 2012255810 A JP2012255810 A JP 2012255810A JP 2013067635 A5 JP2013067635 A5 JP 2013067635A5
Authority
JP
Japan
Prior art keywords
group
concentration
enhancing polymer
surfactants
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012255810A
Other languages
English (en)
Japanese (ja)
Other versions
JP5648038B2 (ja
JP2013067635A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013067635A publication Critical patent/JP2013067635A/ja
Publication of JP2013067635A5 publication Critical patent/JP2013067635A5/ja
Application granted granted Critical
Publication of JP5648038B2 publication Critical patent/JP5648038B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012255810A 2006-02-09 2012-11-22 Cetp阻害剤のポリマー製剤 Expired - Fee Related JP5648038B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77178206P 2006-02-09 2006-02-09
US60/771,782 2006-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008554428A Division JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤

Publications (3)

Publication Number Publication Date
JP2013067635A JP2013067635A (ja) 2013-04-18
JP2013067635A5 true JP2013067635A5 (https=) 2013-09-05
JP5648038B2 JP5648038B2 (ja) 2015-01-07

Family

ID=38198472

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008554428A Expired - Fee Related JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤
JP2012255810A Expired - Fee Related JP5648038B2 (ja) 2006-02-09 2012-11-22 Cetp阻害剤のポリマー製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008554428A Expired - Fee Related JP5773560B2 (ja) 2006-02-09 2007-02-09 Cetp阻害剤のポリマー製剤

Country Status (14)

Country Link
US (1) US8030359B2 (https=)
EP (1) EP1983966B1 (https=)
JP (2) JP5773560B2 (https=)
KR (1) KR101418267B1 (https=)
CN (2) CN103735515A (https=)
AU (1) AU2007212197B2 (https=)
BR (1) BRPI0707584A2 (https=)
CA (1) CA2641451C (https=)
IL (1) IL192977A (https=)
NO (1) NO341326B1 (https=)
NZ (1) NZ569700A (https=)
RU (1) RU2457841C2 (https=)
WO (1) WO2007092642A2 (https=)
ZA (1) ZA200805854B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085996A2 (en) 2003-03-20 2004-10-07 Albert Einstein College Of Medicine Of Yeshiva University Biomarkers for longevity and disease and uses thereof
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006073973A2 (en) * 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
AU2008313620A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product containing N-aryl urea-based compound
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ,インク. プロスタグランジンd2受容体アンタゴニスト
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
AU2011332031B2 (en) 2010-11-24 2017-01-12 Melinta Subsidiary Corp. Pharmaceutical compositions
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
MX368859B (es) 2012-05-31 2019-10-18 Merck Sharp & Dohme Formulaciones de dosis solida de un antagonista del receptor de orexina.
KR102160903B1 (ko) * 2012-07-17 2020-10-05 다우 글로벌 테크놀로지스 엘엘씨 고도로 치환된 하이드록시알킬 메틸셀룰로즈를 포함하는 고체 분산물
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 少なくとも1種の水溶性ビタミンe誘導体および少なくとも1種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US20160287568A1 (en) * 2013-11-22 2016-10-06 Merck Sharp & Dohme Corp. Composition of a non-nucleoside reverse transcriptase inhibitor
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
JP6491669B2 (ja) 2014-02-05 2019-03-27 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Cgrp活性化合物の錠剤製剤
WO2016084949A1 (ja) * 2014-11-28 2016-06-02 興和株式会社 医薬
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN111803632B (zh) * 2019-04-09 2022-04-29 北京五和博澳药业股份有限公司 黄酮多酚类药物自乳化组合物、其制备方法、药物组合物及用途
BR112021020389A2 (pt) * 2019-04-12 2021-12-07 Oblita Therapeutics Bvba Formulações de dosagem em comprimidos de oleil fosfocolina
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2023049920A1 (en) 2021-09-27 2023-03-30 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
ES2284871T3 (es) 2001-06-22 2007-11-16 Pfizer Products Inc. Composiciones farmaceuticas que contienen una dispersion solida de farmaco poco soluble y un polimero potenciador de la solubilidad.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CN100410236C (zh) 2002-01-29 2008-08-13 雪兰诺实验室有限公司 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物
DE60322665D1 (de) * 2002-02-01 2008-09-18 Pfizer Prod Inc Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
PL371593A1 (en) 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
MXPA05009848A (es) 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
US20070043079A1 (en) 2003-04-18 2007-02-22 Hiromu Habashita Heterocyclic compound containing nitrogen atom and use thereof
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
CN102757397A (zh) * 2005-07-01 2012-10-31 默沙东公司 合成cetp抑制剂的方法
EP1965764B1 (en) * 2005-12-05 2011-07-13 Merck Sharp & Dohme Corp. Self-emulsifying formulations of cetp inhibitors

Similar Documents

Publication Publication Date Title
JP2013067635A5 (https=)
RU2014152031A (ru) Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
JP2011225578A5 (https=)
JP2014532638A5 (https=)
JP2013515742A5 (https=)
JP2015147762A5 (https=)
JP2012255026A5 (https=)
JP2017537066A5 (https=)
JP2014167026A5 (https=)
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
HRP20171512T1 (hr) Derivati betulina
MX362709B (es) Microesferas de buprenorfina de fuerte carga de medicamento y su método de fabricación.
JP2013529637A5 (https=)
AR102228A1 (es) Una formulación de metformina de liberación sostenida y un método de preparación de la misma
FR2963250B1 (fr) Emulsion de type huile dans l'eau sans tensioactif, son procede de preparation et ses utilisations
CN109661395A (zh) Pde4抑制剂
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
JOP20170197B1 (ar) الصيغة الجديدة التي تشتمل على مشتق بنزيميدازول
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
JP2012051888A5 (https=)
WO2012117115A3 (de) Verwendung eines viskoelastischen fluids zur herstellung eines medizinproduktes für die chirurgische behandlung des auges
CN109563051A (zh) 作为pde4抑制剂的并环类化合物
JP2014508170A5 (https=)
JP2014526571A5 (https=)
JP2016525410A5 (https=)